Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series
RS Avasare, PA Canetta, AS Bomback… - Clinical Journal of the …, 2018 - journals.lww.com
Results We identified 30 patients who met inclusion criteria. Median age was 25 years old
(interquartile range, 18–36), median creatinine was 1.07 mg/dl (interquartile range, 0.79 …
(interquartile range, 18–36), median creatinine was 1.07 mg/dl (interquartile range, 0.79 …
Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN
MC Marinozzi, LT Roumenina, S Chauvet… - Journal of the …, 2017 - journals.lww.com
Abstract In C3 glomerulopathy (C3G), the alternative pathway of complement is frequently
overactivated by autoantibodies that stabilize the C3 convertase C3bBb. Anti-C3b and anti …
overactivated by autoantibodies that stabilize the C3 convertase C3bBb. Anti-C3b and anti …
[HTML][HTML] Effectiveness of mycophenolate mofetil in C3 glomerulonephritis
C Rabasco, T Cavero, E Román, J Rojas-Rivera… - Kidney international, 2015 - Elsevier
C3 glomerulonephritis is a clinicopathologic entity defined by the presence of isolated or
dominant deposits of C3 on immunofluorescence. To explore the effect of …
dominant deposits of C3 on immunofluorescence. To explore the effect of …
Clinical findings, pathology, and outcomes of C3GN after kidney transplantation
L Zand, EC Lorenz, FG Cosio… - Journal of the …, 2014 - journals.lww.com
Abstract C3 glomerulonephritis (C3GN) results from abnormalities in the alternative pathway
of complement, and it is characterized by deposition of C3 with absent or scant Ig deposition …
of complement, and it is characterized by deposition of C3 with absent or scant Ig deposition …
Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy
S Chauvet, LT Roumenina, P Aucouturier… - Frontiers in …, 2018 - frontiersin.org
C3 glomerulopathy (C3G) results from acquired or genetic abnormalities in the complement
alternative pathway (AP). C3G with monoclonal immunoglobulin (MIg-C3G) was recently …
alternative pathway (AP). C3G with monoclonal immunoglobulin (MIg-C3G) was recently …
Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease
F Caravaca-Fontán… - Clinical Journal of the …, 2020 - journals.lww.com
Results The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense
deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this …
deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this …
Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex–mediated membranoproliferative GN
P Iatropoulos, E Daina, M Curreri, R Piras… - Journal of the …, 2018 - journals.lww.com
Membranoproliferative GN (MPGN) was recently reclassified as alternative pathway
complement–mediated C3 glomerulopathy (C3G) and immune complex–mediated …
complement–mediated C3 glomerulopathy (C3G) and immune complex–mediated …
[HTML][HTML] Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies
A Servais, LH Noël, LT Roumenina, M Le Quintrec… - Kidney international, 2012 - Elsevier
Dense deposit disease and glomerulonephritis with isolated C3 deposits are
glomerulopathies characterized by deposits of C3 within or along the glomerular basement …
glomerulopathies characterized by deposits of C3 within or along the glomerular basement …